2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Ovarian Neoplasms
8
Neoplasms
7
Colorectal Neoplasms
5
Recurrence
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Glioblastoma
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Radiation Pneumonitis
2
Peritoneal Neoplasms
2
Mesothelioma, Malignant
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Rectal Neoplasms
1
Patients With Any Advanced Solid Tumors
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Interventions
Carboplatin
71
Paclitaxel
49
Radiotherapy
44
Pemetrexed
42
Cisplatin
41
Bevacizumab
39
Gemcitabine
27
Docetaxel
27
Erlotinib Hydrochloride
23
Gefitinib
18
pembrolizumab
14
Taxes
13
Vinorelbine
10
Cetuximab
10
Radiation
8
Nivolumab
8
Magnetic Resonance Spectroscopy
8
capmatinib
7
Radiosurgery
7
Platinum
7
Etoposide
7
Surgical Procedures, Operative
6
Radiotherapy, Conformal
6
Mastectomy, Segmental
6
ceritinib
5
aflutinib
5
Specimen Handling
5
Neoadjuvant Therapy
5
Cyclophosphamide
5
Biopsy
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
nintedanib
×
Clear all
NCT03361319
2020-11-24
N3
Royal Marsden NHS Foundation Trust
Phase 1/2
Withdrawn